

Total number of patients (n)	1438
Age (years $\pm$ SD)	54.9 $\pm$ 14.9
Females, n (%)	849 (59 %)
Diagnosis, n (%)	
Rheumatoid arthritis	500 (34.8 %)
Psoriatic arthritis	378 (26.3 %)
Ankylosing spondylitis	309 (21.5 %)
Unspecified polyarthritis	77 (5.4 %)
Not registered	48 (3.3 %)
Reactive arthritis	37 (2.6 %)
Systemic lupus erythematosus	19 (1.3 %)
Juvenile idiopathic arthritis	13 (0.9%)
Giant cell arteritis	10 (0.7%)
Other disorders/diagnosis	47 (3.3 %)
Targeted DMARDS, n (%)	
TNF inhibitors	1225 (85.2 %)
<i>Infliximab</i>	436 (30.3 %)
<i>Etanercept</i>	343 (23.9 %)
<i>Adalimumab</i>	309 (21.5 %)
<i>Golimumab</i>	137 (9.5 %)
<i>Certolizumab</i>	3 (0.2%)
Tocilizumab	82 (5.7 %)
Secukinumab	51 (3.5 %)
Rituximab	26 (1.8 %)
Belimumab	17 (1.2 %)
Tofacitinib	10 (0.7 %)
Abatacept	9 (0.6 %)
Ustekinumab	8 (0.6 %)
Anakinra	5 (0.4%)
Apremilast	2 (0.1 %)
<i>Table S2</i>	
<i>Baseline demographics of 1438 rheumatic patients in ICEBIO in respect to disease and treatment</i>	